【摘要】 目的探讨肝动脉栓塞化疗联合中药复方制剂肝复乐胶囊对晚期肝癌的远期疗效。方法连续的197个肝功能Child-pugh A/B级晚期肝癌患者,根据患者意愿分到肝动脉栓塞化疗(transcatheter arterial chemoembolization,TACE)联合肝复乐组(66例)、单纯TACE组(64)和单纯肝复乐组(67例)。主要评价终点指标为总生存率,并进行预后因素分析。结果 TACE联合肝复乐组、单纯TACE组以及单纯肝复乐组的中位生存期分别为19个月[95%confidence interval(CI),10.659～27.341个月]、9个月(95%CI,6.508～11.452个月)和5个月(95%CI,3.853～6.147个月)(P<0.05)。TACE联合肝复乐组半年、1年、2年总生存率分别为98.5%、59.1%、36.8%;单纯TACE组半年、1年、2年总生存率分别为63.8%、34.1%、20.2%;单纯肝复乐组半年、1年、2年总生存率分别为38.5%、17.5%、1.8%。门脉主干瘤栓和ECOG体力状态评分是影响预后的独立因素。结论肝动脉栓塞化疗联合中药复方制剂肝复乐能明显延长患者生存期。影响晚期肝癌患者预后的主要因素是门脉主干瘤栓和ECOG体力状态评分。更多还原

【Abstract】 Objective To evaluate the efficacy of transcatheter arterial chemoembolization(TACE) combined with a Chinese compound preparation of Ganfule on advanced hepatocellular carcinoma(HCC).Methods The study population consisted of 197 advanced HCC patients with Child-pugh A/B.TACE combined with Ganfule was performed on 66 patients with advanced HCC,64 patients were treated with TACE,and 67 patients were treated with Ganfule.The prime end point was the overall survival,and the prognostic factors were analysed.Results The median OS was 19 months [95% confidence interval(CI),10.659-27.341 months] in the TACE combined with Ganfule group,9 months(95% CI,6.508-11.452 months) in the TACE group,and 5 months(95% CI,3.853-6.147 months) in the Ganfule group(P < 0.05).The 6-month,1-year,and 2-year overall survival rates were 98.5%,59.1%,and 36.8% in the TACE combined with Ganfule group,and 63.8%,34.1%,and 20.2% in the TACE group,and 38.5%,17.5%,and 1.8% in the Ganfule group.The portal vein thrombosis,and ECOG performance were independent prognostic factors for overall survival.Conclusion TACE combined with Ganfule capsules can greatly prolong the overall survival in patients with advanced HCC.The portal vein thrombosis and ECOG performance are independent prognostic factors for overall survival.更多还原